IL6 and COVID-19: In the case of severe patients, there are several agents with demonstrated in vitro activity against COVID-19 used in clinical practice, including hydroxychloroquine, remdesivir, interleukin-6 pathway inhibitors, and convalescent plasma; however, to date few agents have proven efficacy against COVID-19 [10].